Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

AZEDRA

IOBENGUANE I-131

Standard Dose
15mCi/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview AZEDRA is listed in Drugs@FDA under application 209607 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient IOBENGUANE I-131 Form and strength SOLUTION;INTRAVENOUS - 15mCi/ML Sponsor PROGENICS PHARMS INC Submission history Latest submission status date: 2023-02-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview AZEDRA is listed in Drugs@FDA under application 209607 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient IOBENGUANE I-131 Form and strength SOLUTION;INTRAVENOUS - 15mCi/ML Sponsor PROGENICS PHARMS INC Submission history Latest submission status date: 2023-02-14 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.